ACT Genomics joins force with Sanomics



The next-generation oncology diagnostic powerhouse is formed in Asia, ACT Genomics and Sanomics offering total solutions to patients, medical professionals, pharmaceutical companies, and research institutes globally.

ACT Genomics Holdings Company Limited (“ACT Genomics”), a leading cancer solution provider in Asia, has joined force with Sanomics Holdings Limited (“Sanomics”), a champion in lung cancer diagnostic in Hong Kong and Thailand.

The acquisition by ACT Genomics creates an integrated oncology diagnostic powerhouse in Asia. It offers a wide range of innovative and state-of-the-art products for both tissue and liquid-based tests, multiple diagnostic technology platforms including NGS, digital PCR and gene-chips, and services covering most cancer types of different stages in clinical applications as well as assisting pharmaceutical companies in companion diagnostics development and drugs discovery. 

According to GLOBOCAN’s latest cancer statistics, an estimated 19.3 million new cancer cases and 9.9 million cancer deaths occurred worldwide in 2020, among which 49.3% of all cases and 58.3% of cancer deaths are estimated to have occurred in Asia. In contrast to other regions, the share of cancer deaths in Asia (58.3%) and Africa (7.2%) are higher than the share of incidence (49.3% and 5.7%, respectively) because of the different distribution of cancer types and higher case fatality rates in these regions. Lung cancer is the leading cause of cancer death, and accounted for 18%, followed by colorectum cancer at 9.4% in 2020. 

The combined group has four wholly owned laboratories, two in Hong Kong, one in Taipei and one in Bangkok, among which three (Hong Kong and Taipei) are CAP-accredited. The group also has a CAP-accredited laboratory in Kanagawa (Japan) under its joint venture with Canon Medical Systems, and one more newly formed laboratory in Taipei under another joint venture with Cerba Research on IHC/Flow Cytometry.  The enlarged company has presences in Hong Kong, Taipei, Tokyo, Singapore, Bangkok and the Wales (UK). This helps promote a synergistic competitive advantage in serving the medical and pharmaceutical communities on the ground in Asia and Europe. 

Dr. Hua Chien Chen, Founder of ACT Genomics, says “The union of ACT Genomics and Sanomics will significantly broaden our horizon in terms of product offerings, business strategy and vision.
The combined group will be better able to take advantage of our respective clear leadership positions and form a next generation oncology diagnostics powerhouse with a keen devotion to ESG in Asia.” 

Prof. Tony Mok, Chairman of Sanomics, says “We are very excited in joining the ACT Genomics big family. Our team is ready to make meaningful contributions to the enlarged group with our technical expertise, especially in the field of lung cancer, as well as firsthand clinical experience. The synergy and combined resources will enable us to provide more comprehensive solutions and better services to clinicians and put patients first!  This merger will enable us to further extend our reach to more patients and pharmaceutical companies in greater geographies.  

Both ACT Genomics and Sanomics were awarded the Elite Program funding by the Hong Kong Science and Technology Park. On top of solid endorsement given to both companies by industry experts, 100% of the grants have been used in Research & Development which is the core value of the enlarged group’s culture in technology excellence.